by David Kent | Apr 15, 2014
> In February this year, the biggest stem cell trial for heart attack patients was begun and will involve over 3000 patients from 11 different countries in Europe. The BAMI trial (the effect of intracoronary reinfusion of Bone marrow-derived mononuclear cells on...
by Alessandra Pasut | Apr 2, 2014
Editor’s note: Some of the links included are Italian language sources The case involving Stamina Foundation and the legitimacy of its stem cell treatments has been one of the most discussed and controversial issues in the international stem cell policy scene....
by Sara M. Nolte | Mar 4, 2014
> A little while ago, I wrote a post about the BRCA1 gene and its role in breast cancer, and suggested that Angelina Jolie’s mastectomy reveal was a missed opportunity to provide information about hereditary breast cancer. I have since wondered what did we get out...
by Sara M. Nolte | Jan 15, 2014
> I have recently been transitioning from “basic” science research to science communication. Why? Because there is a great disparity in what the public, policy makers, and even clinicians, know and think about research, and what the researchers know. I believe as...
by Natasha Davie | Dec 10, 2013
. The UK has previously committed to incorporating some sort of value based pricing into its reimbursement scheme to improve patient access to innovative medicines. With recent backtracking on this decision, as the Jan 2014 deadline for this integration approaches, we...
by Nick Dragojlovic | Dec 2, 2013
> As the expiration of the California Institute for Regenerative Medicine’s (CIRM) funding approaches, the fate of CIRM after 2017 is top of mind for stem cell researchers in the state. While the agency’s leadership appears to be leaning towards some form of...
Comments